Epidermal growth factor for ulcerative colitis

New England Journal of Medicine

Volumn 349, Issue 4, 2003, Pages 395-397

  Farrell, Richard J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MESALAZINE; SALAZOSULFAPYRIDINE; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; TREFOIL PEPTIDE; ENEMA; EPIDERMAL GROWTH FACTOR; NONSTEROID ANTIINFLAMMATORY AGENT;

ANTIINFLAMMATORY ACTIVITY; COLON MUCOSA; EDITORIAL; IMMUNOMODULATION; INTESTINE FLORA; PRIORITY JOURNAL; ULCERATIVE COLITIS; WOUND HEALING; DRUG COMBINATION; HUMAN; NOTE; ORAL DRUG ADMINISTRATION; PROCTITIS; REMISSION;

ADMINISTRATION, ORAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; DRUG THERAPY, COMBINATION; ENEMA; EPIDERMAL GROWTH FACTOR; HUMANS; MESALAMINE; PROCTITIS; REMISSION INDUCTION;

EID: 0038793307     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMe030075     Document Type: Editorial

References (16)

1. Farrell RJ, Peppercorn MA. Ulcerative colitis. Lancet 2002;359: 331-40.
2. Pullan RD, Ganesh S, Mani V, et al. Comparison of bismuth citrate and 5-aminosalicylic acid enemas in distal ulcerative colitis: a controlled trial. Gut 1993;34:676-9.
3. Kono T, Nomura M, Kasai S, Kohgo Y. Effect of ecabet sodium enema on mildly to moderately active ulcerative proctosigmoiditis: an open-label study. Am J Gastroenterol 2001;96:793-7.
4. Beck PL, Podolsky DK. Growth factors in inflammatory bowel disease. Inflamm Bowel Dis 1999;5:44-60.
5. Sinha A, Nightingale JMD, West KP, Berlanga-Acosta J, Playford RJ. Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. N Engl J Med 2003;349:350-7.
6. Hanauer S, Schwartz J, Robinson M, et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Am J Gastroenterol 1993;88:1188-97.
7. Safdi M, DeMicco M, Sninsky C, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 1997; 92:1867-71.
8. Sutherland L, Roth D, Beck P, May G, Makiyama K. Oral 5-aminosalicylic acid for inducing remission in ulcerative colitis. Cochrane Database Syst Rev 2000;2:CD000543.
9. Falasco G, Zinicola R, Forbes A. Immunosuppressants in distal ulcerative colitis. Aliment Pharmacol Ther 2002;16:181-7.
10. Ording Olsen K, Juul S, Berndtsson I, Oresland T, Laurberg S. Ulcerative colitis: female fecundity before diagnosis, during disease, and after surgery compared with a population sample. Gastroenterology 2002;122:15-9.
11. Guslandi M, Frego R, Viale E, Testoni PA. Distal ulcerative colitis refractory to rectal mesalamine: role of transdermal nicotine versus oral mesalamine. Can J Gastroenterol 2002;16:293-6.
12. Stenson WF, Cort D, Rodgers J, et al. Dietary supplementation with fish oil in ulcerative colitis. Ann Intern Med 1992;116:609-14.
13. Breuer RI, Soergel KH, Lashner BA, et al. Short chain fatty acid rectal irrigation for left-sided ulcerative colitis: a randomised, placebo controlled trial. Gut 1997;40:485-91.
14. Chowdhury A, Fukuda R, Fukumoto S. Growth factor mRNA expression in normal colorectal mucosa and in uninvolved mucosa from ulcerative colitis patients. J Gastroenterol 1996;31:353-60.
15. Babyatsky MW, Rossiter G, Podolsky DK. Expression of transforming growth factors alpha and beta in colonic mucosa in inflammatory bowel disease. Gastroenterology 1996;110:975-84.
16. Eaden J, Abrams K, Ekbom A, Jackson E, Mayberry J. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther 2000;14:145-53.